Literature DB >> 8920825

Selection of hepatitis C virus quasispecies during interferon treatment.

I Sakuma1, N Enomoto, M Kurosaki, F Marumo, C Sato.   

Abstract

Preliminary studies have shown that hepatitis C virus (HCV) quasispecies populations after interferon therapy are different from those before interferon, suggesting that selection of HCV quasispecies occurs during IFN treatment. To confirm this, fluctuations of HCV quasispecies populations were investigated by single strand conformation polymorphism analysis in eight patients who remained viremic during interferon treatment. In all patients, HCV quasispecies populations changed in 1 to 4 months after the start of interferon therapy. In seven patients, a minor population of HCV quasispecies that was present before the interferon therapy was selected and became predominant during the therapy, whereas the abundance of the other quasispecies was reduced. In the other patients, new HCV quasispecies that had not been detected before interferon therapy appeared and replaced the pretreatment HCV. In contrast, no significant changes were observed during the pretreatment period in these patients. In two patients, deduced amino acid sequences of the hypervariable region were identical despite the difference in nucleotide sequences between interferon-sensitive and interferon-resistant HCV. Thus, selection of HCV quasispecies occurs during interferon treatment and immune responses to the hypervariable region may not be the determining factor of the selection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8920825     DOI: 10.1007/bf01718204

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  41 in total

1.  Nonisotopic SSCP detection in PCR products by ethidium bromide staining.

Authors:  E P Yap; J O McGee
Journal:  Trends Genet       Date:  1992-02       Impact factor: 11.639

2.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction.

Authors:  M Orita; Y Suzuki; T Sekiya; K Hayashi
Journal:  Genomics       Date:  1989-11       Impact factor: 5.736

Review 3.  RNA virus populations as quasispecies.

Authors:  J J Holland; J C De La Torre; D A Steinhauer
Journal:  Curr Top Microbiol Immunol       Date:  1992       Impact factor: 4.291

4.  Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

Authors:  G L Davis; L A Balart; E R Schiff; K Lindsay; H C Bodenheimer; R P Perrillo; W Carey; I M Jacobson; J Payne; J L Dienstag
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

5.  Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis.

Authors:  N Kato; M Hijikata; Y Ootsuyama; M Nakagawa; S Ohkoshi; T Sugimura; K Shimotohno
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

6.  Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single-strand conformation polymorphism analysis.

Authors:  N Enomoto; M Kurosaki; Y Tanaka; F Marumo; C Sato
Journal:  J Gen Virol       Date:  1994-06       Impact factor: 3.891

7.  Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus.

Authors:  K Yoshioka; S Kakumu; T Wakita; T Ishikawa; Y Itoh; M Takayanagi; Y Higashi; M Shibata; T Morishima
Journal:  Hepatology       Date:  1992-08       Impact factor: 17.425

8.  Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection.

Authors:  N Enomoto; I Sakuma; Y Asahina; M Kurosaki; T Murakami; C Yamamoto; Y Ogura; N Izumi; F Marumo; C Sato
Journal:  N Engl J Med       Date:  1996-01-11       Impact factor: 91.245

9.  Genetic alterations of the putative envelope proteins encoding region of the hepatitis C virus in the progression to relapsed phase from acute hepatitis: humoral immune response to hypervariable region 1.

Authors:  H Sekiya; N Kato; Y Ootsuyama; T Nakazawa; K Yamauchi; K Shimotohno
Journal:  Int J Cancer       Date:  1994-06-01       Impact factor: 7.396

10.  Rapid sequence variation of the hypervariable region of hepatitis C virus during the course of chronic infection.

Authors:  M Kurosaki; N Enomoto; F Marumo; C Sato
Journal:  Hepatology       Date:  1993-12       Impact factor: 17.425

View more
  7 in total

1.  Combined therapy with interferon and ribavirin in chronic hepatitis C does not affect serum quasispecies diversity.

Authors:  S Sookoian; G Castaño; B Frider; J Cello; R Campos; D Flichman
Journal:  Dig Dis Sci       Date:  2001-05       Impact factor: 3.199

Review 2.  The evolution of bovine viral diarrhea: a review.

Authors:  S Denise Goens
Journal:  Can Vet J       Date:  2002-12       Impact factor: 1.008

3.  Significance of pretreatment analysis of hepatitis C virus genotype 1b hypervariable region 1 sequences to predict antiviral outcome.

Authors:  Catherine Gaudy; Alain Moreau; Pascal Veillon; Stephanie Temoin; Francoise Lunel; Alain Goudeau
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

4.  Activation and evasion of the antiviral 2'-5' oligoadenylate synthetase/ribonuclease L pathway by hepatitis C virus mRNA.

Authors:  Jian-Qiu Han; David J Barton
Journal:  RNA       Date:  2002-04       Impact factor: 4.942

5.  Quasispecies of genotype 4 of hepatitis C virus genomes in Saudi patients managed with interferon alfa and ribavirin therapy.

Authors:  Ahmed A Al-Qahtani; George Kessie; Damian Dela Cruz; Faleh Z Al-Faleh; Mohammed N Al-Ahdal
Journal:  Ann Saudi Med       Date:  2010 Mar-Apr       Impact factor: 1.526

Review 6.  [Characteristics of the hepatitis C virus and viral predictors of therapeutic response].

Authors:  A Ambrosch; W König
Journal:  Med Klin (Munich)       Date:  1999-11-15

7.  Replicative homeostasis: a fundamental mechanism mediating selective viral replication and escape mutation.

Authors:  Richard Sallie
Journal:  Virol J       Date:  2005-02-11       Impact factor: 4.099

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.